Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (8229)	1/7/1999 11:58:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

David, I am not really sure about that. The hu1124 story has been know for sometime. If anything we are seeing normal profit taking and perhaps hesitation to buy as the implications of the news are thought thru. I honestly don't know if I should be that happy about the news. It seems like an early warning that hu1124 will go back in house at Geneteck. Is this good or bad for XOMA? I would rather have it stay with XOMA as cost were funded by GNE, Xoma earned milestone payments but if it goes back XOMA will be able to focus more on BPI. I am also afraid that since XOMA needs cash it will, if and when hu1124 becomes a product, take a cash payment rather than a share of the profits. But since one does not know what the profit sharing would entail nor the size of any final payment one is left not knowing how good this good news really is. It obviously was good news but I did not feel compelled to buy more because of it, rather I felt perplexed.